Cited by 101Bone health and osteoporosis researchBone Metabolism and DiseasesBone health and treatments

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

Romosozumab for the treatment of osteoporosis

Bandeira, Leonardo, Lewiecki, E. Michael, Bilezikian, John P.·2017·Expert Opinion on Biological Therapy

DOI 10.1080/14712598.2017.1280455

Open this paper in CoChat — free account

Abstract

Introduction Sclerostin, a glycoprotein produced primarily by osteocytes, blocks the canonical Wnt signaling bone formation pathway. Romosozumab is a humanized monoclonal antibody to sclerostin that binds to sclerostin, permitting the engagement of Wnt ligands with their co-receptors, resulting in an increase in bone formation and bone mineral density (BMD). Clinical studies with romosozumab have shown dramatic improvements in BMD at the spine and hip. Romosozumab is associated with improvement in bone strength through mechanisms that include increases in bone formation and, different from classical osteoanabolic agents, suppression of bone resorption. Areas covered: Herein, the authors highlight the available data on romosozumab for the treatment of osteoporosis. This includes the latest data on the efficacy, pharmacokinetics and pharmacodynamics as well as safety and tolerability data. Expert opinion: Monthly subcutaneous dosing of romosozumab reduces the risk of vertebral and clinical fractures in women with postmenopausal osteoporosis, with a favorable balance of benefits and risks. Romosozumab is a promising emerging anabolic agent with a novel mechanism of action that may expand the options for treating osteoporotic patients at high risk of fracture.

Integrity signals

Registry

Crossref · 10.1080/14712598.2017.1280455

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Clinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149
Self-citation
The diagnosis of osteoporosis
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C. C., Rizzoli, R., & Reginster, J. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2074-y · Cited by 2,993
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Harris, S. T. (1999) · JAMA · doi:10.1001/jama.282.14.1344 · Cited by 2,475
Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research
Shane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
WNT signalling pathways as therapeutic targets in cancer
Anastas, J. N., & Moon, R. T. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3419 · Cited by 1,945
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607948 · Cited by 1,805
Self-citation
The Recent Prevalence of Osteoporosis and Low Bone Mass in the United States Based on Bone Mineral Density at the Femoral Neck or Lumbar Spine
Wright, N. C., Looker, A. C., Saag, K. G., Curtis, J. R., Delzell, E. S., Randall, S., & Dawson-Hughes, B. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2269 · Cited by 1,801
Canonical wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
Glass, D. A., Bialek, P., Ahn, J. D., Starbuck, M., Patel, M. S., Clevers, H., Taketo, M. M., Long, F., McMahon, A. P., Lang, R. A., et al. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.02.017 · Cited by 1,558
A systematic review of hip fracture incidence and probability of fracture worldwide
Kanis, J. A., Odén, A., McCloskey, E. V., Johansson, H., Wahl, D. A., Cooper, C. C., & on behalf of the IOF Working Group on Epidemiology and Quality of Life (2012) · Osteoporosis International · doi:10.1007/s00198-012-1964-3 · Cited by 1,382
Prevalence of low femoral bone density in older U.S. women from NHANES III
Looker, A. C., Johnston, C. C., Wahner, H. W., Dunn, W. L., Calvo, M. S., Harris, T. B., Heyse, S. P., & Lindsay, R. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650100517 · Cited by 1,379
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1305224 · Cited by 1,258
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016--Executive Summary
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.esgl · Cited by 1,140
Self-citation
Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research
Shane, E., Burr, D., Ebeling, P. R., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.253 · Cited by 1,116
Prevalence of Low Femoral Bone Density in Older U.S. Adults from NHANES III
Looker, A. C., ORWOLL, E. S., Johnston, C. C., Lindsay, R., Wahner, H. W., Dunn, W. L., Calvo, M. S., Harris, T. B., & Heyse, S. P. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.11.1761 · Cited by 1,052
Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot–Containing Protein
Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength
Li, X., Ominsky, M. S., Niu, Q., Sun, N., Daugherty, B., D’Agostin, D. M., Kurahara, C., Gao, Y., Cao, J., Gong, J., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080216 · Cited by 941
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
Padhi, D., Jang, G. R., Stouch, B., Fang, L., & Posvar, E. L. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.173 · Cited by 786
Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis
Li, X., Ominsky, M. S., Warmington, K. S., Morony, S., Gong, J., Cao, J., Gao, Y., Shalhoub, V., Tipton, B., Haldankar, R., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081206 · Cited by 784
Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease
Balemans, W., Patel, N., Ebeling, M., Van Hul, E., Wuyts, W., Lacza, C., Dioszegi, M., Dikkers, F. G., Hildering, P., Willems, P. J., et al. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.2.91 · Cited by 698
Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety
Vahle, J. L., Sato, M., Long, G. G., Young, J. K., Francis, P. C., Engelhardt, J. A., Westmore, M. S., Ma, Y. L., & Nold, J. B. (2002) · Toxicologic Pathology · doi:10.1080/01926230252929882 · Cited by 694
Mechanisms of Anabolic Therapies for Osteoporosis
CANALIS, E. M., Giustina, A., & Bilezikian, J. P. (2007) · New England Journal of Medicine · doi:10.1056/nejmra067395 · Cited by 675
Self-citation
SOST is a target gene for PTH in bone
Keller, H., & Kneissel, M. (2005) · Bone · doi:10.1016/j.bone.2005.03.018 · Cited by 618
Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study
Pols, H. A. P., Felsenberg, D., Hanley, D. A., Stepan, J. J., Muñoz‐Torres, M., Wilkin, T. J., Ge, Q.-S., Galich, A. M., Vandormael, K., Yates, A. J. P., et al. (1999) · Osteoporosis International · doi:10.1007/pl00004171 · Cited by 586
American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.gl · Cited by 491
Self-citation
Three decades of Wnts: a personal perspective on how a scientific field developed
Nusse, R., & VARMUS, H. E. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.146 · Cited by 427
Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength
Ominsky, M. S., Vlasseros, F., Jolette, J., Smith, S. Y., Stouch, B., Doellgast, G. J., Gong, J., Gao, Y., Cao, J., Graham, K. C., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.14 · Cited by 414
Osteoporosis Medication Use After Hip Fracture in U.S. Patients Between 2002 and 2011
Solomon, D. H., Johnston, S. S., Boytsov, N. N., McMorrow, D., Lane, J. M., & Krohn, K. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2202 · Cited by 366
Bone Remodeling Increases Substantially in the Years After Menopause and Remains Increased in Older Osteoporosis Patients
Recker, R. R., Lappe, J. M., Davies, K. M., & Heaney, R. P. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040710 · Cited by 342
Wnt signalling in osteoblasts regulates expression of the receptor activator of NFκB ligand and inhibits osteoclastogenesis in vitro
Spencer, G. J., Utting, J. C., Etheridge, S. L., Arnett, T. R., & Genever, P. G. (2006) · Journal of Cell Science · doi:10.1242/jcs.02883 · Cited by 341
The US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 years
Andrews, E. B., Gilsenan, A., Midkiff, K. D., Sherrill, B. H., Wu, Y., Mann, B. H., & Masica, D. N. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1768 · Cited by 272
Bone Modeling and Remodeling
Seeman, E. (2009) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v19.i3.40 · Cited by 242
Involvement of WNT/β-catenin Signaling in the Treatment of Osteoporosis
Rossini, M., Gatti, D., & Adami, S. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9749-z · Cited by 239
Characterization of the Structural Features and Interactions of Sclerostin
Veverka, V., Henry, A. J., Slocombe, P. M., Ventom, A. M., Mulloy, B., Muskett, F. W., Muzylak, M., Greenslade, K. J., Moore, A., Zhang, L., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807994200 · Cited by 236
Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats
Li, X., Warmington, K. S., Niu, Q., Asuncion, F., Barrero, M., Grisanti, M. S., Dwyer, D., Stouch, B., Thway, T. M., Stolina, M., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.182 · Cited by 231
Teriparatide for osteoporosis: importance of the full course
Lindsay, R., Krege, J. H., Marín, F. R., Jin, L., & Stepan, J. J. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3534-6 · Cited by 211
Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study
Padhi, D., Allison, M. J., Kivitz, A., Gutierrez, M. J., Stouch, B., Wang, C., & Jang, G. R. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.239 · Cited by 185
Biphasic and Dosage-Dependent Regulation of Osteoclastogenesis by β-Catenin
Wei, W., Zeve, D., Suh, J. M., Wang, X., Du, Y., Zerwekh, J. E., Dechow, P. C., Graff, J. M., & Wan, Y. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05980-11 · Cited by 183
Bone Mineral Density in Sclerosteosis; Affected Individuals and Gene Carriers
Gardner, J. C., van Bezooijen, R. L., Mervis, B., Hamdy, N. A. T., Löwik, C. W. G. M., Hamersma, H. A., Beighton, P., & Papapoulos, S. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1235 · Cited by 179
Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model
Tian, X., Jee, W. S. S., Li, X., Pászty, C., & Ke, H. Z. (2010) · Bone · doi:10.1016/j.bone.2010.09.009 · Cited by 177
An Uncommon Familial Systemic Disease of the Skeleton: Hyperostosis Corticalis Generalisata Familiaris
van Buchem, F. S. P., Hadders, H. N., & Ubbens, R. (1955) · Acta Radiologica · doi:10.3109/00016925509170789 · Cited by 148
Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass
Genant, H. K., Engelke, K., Bolognese, M. A., Mautalén, C., Brown, J. P., Recknor, C. P., Goemaere, S., Fuerst, T. P., Yang, Y., Grauer, A., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2932 · Cited by 143
Sclerostin antibody treatment enhances metaphyseal bone healing in rats
Agholme, F., Li, X., Isaksson, H., Ke, H. Z., & Aspenberg, P. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.135 · Cited by 142
Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002–2012
Wysowski, D. K., & Greene, P. (2013) · Bone · doi:10.1016/j.bone.2013.09.008 · Cited by 139
Patients with sclerosteosis and disease carriers: Human models of the effect of sclerostin on bone turnover
van Lierop, A. H., Hamdy, N. A. T., Hamersma, H. A., van Bezooijen, R. L., Power, J., Loveridge, N., & Papapoulos, S. E. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.474 · Cited by 133
A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities.
Babcook, J. S., Leslie, K. B., Olsen, O. A., Salmon, R. A., & Schrader, J. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7843 · Cited by 132
The use of parathyroid hormone in the treatment of osteoporosis
Girotra, M., Rubin, M. R., & Bilezikian, J. P. (2006) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-006-9007-z · Cited by 125
Self-citation
Incidence of hip fracture in Brazil and the development of a FRAX model
Zerbini, C. A. F., Szejnfeld, V. L., Abergaria, B. H., McCloskey, E. V., Johansson, H., & Kanis, J. A. (2015) · Archives of Osteoporosis · doi:10.1007/s11657-015-0224-5 · Cited by 114
A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis
Cianferotti, L., D’Asta, F., & Brandi, M. L. (2013) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x13483187 · Cited by 111
Latitude, socioeconomic prosperity, mobile phones and hip fracture risk
Johnell, O., Borgström, F., Jönsson, B., & Kanis, J. A. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0245-4 · Cited by 107
Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys
Ominsky, M. S., Boyd, S. K., Varela, A., Jolette, J., Felx, M., Doyle, N. E., Mellal, N., Smith, S. Y., Locher, K., Buntich, S., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3036 · Cited by 104
Patients with Van Buchem Disease, an Osteosclerotic Genetic Disease, Have Elevated Bone Formation Markers, Higher Bone Density, and Greater Derived Polar Moment of Inertia than Normal
Wergedal, J. E., Veskovic, K., Hellan, M., Nyght, C., Balemans, W., Libanati, C. R., Vanhoenacker, F. M. H. M., Tan, J., Baylink, D. J., & Hul, W. V. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030201 · Cited by 98
A Short Treatment With an Antibody to Sclerostin Can Inhibit Bone Loss in an Ongoing Model of Colitis
Eddleston, A., Marenzana, M., Moore, A., Stephens, P. E., Muzylak, M., Marshall, D., & Robinson, M. K. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090403 · Cited by 98
Sclerosteosis
Stein, S. A., Witkop, C. J., Hill, S. C., Fallon, M. D., Viernstein, L. J., Gucer, G., McKeever, P. E., Long, D. M., Altman, J., Miller, N. R., et al. (1983) · Neurology · doi:10.1212/wnl.33.3.267 · Cited by 97
Increased Bone Formation and Bone Mass Induced by Sclerostin Antibody Is Not Affected by Pretreatment or Cotreatment with Alendronate in Osteopenic, Ovariectomized Rats
Li, X., Ominsky, M. S., Warmington, K. S., Niu, Q., Asuncion, F., Barrero, M., Dwyer, D., Grisanti, M. S., Stolina, M., Kostenuik, P. J., et al. (2011) · Endocrinology · doi:10.1210/en.2011-0252 · Cited by 87
Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study
Chouinard, L., Felx, M., Mellal, N., Varela, A., Mann, P., Jolette, J., Samadfam, R., Smith, S. Y., Locher, K., Buntich, S., et al. (2016) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2016.08.010 · Cited by 84
Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis
Graeff, C., Campbell, G. M., Peña, J. A., Borggrefe, J., Padhi, D., Kaufman, A., Chang, S., Libanati, C. R., & Glüer, C. (2015) · Bone · doi:10.1016/j.bone.2015.07.036 · Cited by 79
Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene
Li, C., Ominsky, M. S., Tan, H., Barrero, M., Niu, Q., Asuncion, F., Lee, E. W., Liu, M., Simonet, W. S., Pászty, C., et al. (2011) · Bone · doi:10.1016/j.bone.2011.08.012 · Cited by 73
Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone
Marenzana, M., Greenslade, K. J., Eddleston, A., Okoye, R., Marshall, D. R., Moore, A., & Robinson, M. K. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30385 · Cited by 73
Sclerostin: Therapeutic Horizons Based Upon Its Actions
Costa, A. G., & Bilezikian, J. P. (2012) · Current Osteoporosis Reports · doi:10.1007/s11914-011-0089-5 · Cited by 72
Self-citation
Osteopetrosis with syndactyly; a morphological variant of Albers-Schönberg's disease.
As, T. (1958) · PubMed · Cited by 71
Anabolic effects of PTH and the ‘anabolic window’
Pazianas, M. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.01.004 · Cited by 31
Emerging Therapies for Osteoporosis
McClung, M. R. (2015) · Endocrinology and Metabolism · doi:10.3803/enm.2015.30.4.429 · Cited by 30
New insights into treatment of osteoporosis in postmenopausal women
Geusens, P. (2015) · RMD Open · doi:10.1136/rmdopen-2015-000051 · Cited by 26
Meta‐analysis about efficacy of anti‐resorptive drugs in post‐menopausal osteoporosis
de Macedo, J. M. S., Macedo, C. R. B., Elkis, H., & Oliveira, I. R. D. (1998) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.1998.00168.x · Cited by 25
Analyses of bone modeling and remodeling using in vitro reconstitution system with two-photon microscopy
Hikita, A., Iimura, T., Oshima, Y., Saitou, T., Yamamoto, S., & Imamura, T. (2015) · Bone · doi:10.1016/j.bone.2015.02.030 · Cited by 20
Acting on black box warnings requires a GRADE evidence table and an implementation guide: the case of teriparatide
Elraiyah, T. A., Gionfriddo, M. R., & Murad, M. H. (2015) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2015.01.025 · Cited by 13
Biphasic and dosage-dependent regulation of osteoclastogenesis by beta-catenin
Wan, Y., Wei, W., Zeve, D., Suh, J. M., Wang, X., Du, Y., Zerwekh, J. E., Dechow, P. C., & Graff, J. M. (2011) · Bone · doi:10.1016/j.bone.2011.03.353 · Cited by 9
Superior Gains in Bone Mineral Density (BMD) and Estimated Strength at the Hip for Romosozumab Compared With Teriparatide (TPTD) in Women With Postmenopausal Osteoporosis Transitioning From Bisphosphonate Therapy: Results of the Phase 3 Open-label STRUCTURE Study
Langdahl, B. L., Libanati, C. R., Crittenden, D. B., Bolognese, M. A., Brown, J. P., Daizadeh, N. S., Dokoupilová, E., Engelke, K., Finkelstein, J. S., Genant, H. K., et al. (2016) · Bone Abstracts · doi:10.1530/boneabs.5.ht5 · Cited by 7

Research works printed but not linked: 3

Holanda NCP, 2015, Endocrinologia e Diabetes, 457
Truswell AS, 1958, J Bone Joint Surg Br, 40, 209
Genant HK, 2016, J Bone Miner Res, 1

Sorted by citations

Osteoporosis in Older Adults
Johnston, C. B., & Dagar, M. (2020) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.06.004 · Cited by 666
Osteoporosis pathogenesis and treatment: existing and emerging avenues
Liang, B., Burley, G., Lin, S., & Shi, Y. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00371-3 · Cited by 250
Osteoporosis: Mechanism, Molecular Target and Current Status on Drug Development
Li, H., Xiao, Z., Quarles, L. D., & Li, W. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867327666200330142432 · Cited by 226
Osteoporosis in patients with chronic kidney diseases: A systemic review
Hsu, C.-Y., Chen, L.-R., & Chen, K.-H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186846 · Cited by 162
Insights and implications of sexual dimorphism in osteoporosis
Zhang, Y., Xie, N., Sun, X., Nice, E. C., Liou, Y., Huang, C., Zhu, H., & Shen, Z. (2024) · Bone Research · doi:10.1038/s41413-023-00306-4 · Cited by 164

See all 101

Authors: Bandeira, L., Lewiecki, E. M., & Bilezikian, J. P.
Affiliations: Columbia University Irving Medical Center (US)
New Mexico Clinical Research & Osteoporosis Center (US)
Corresponding author: Lewiecki, E. Michael
ORCID: Bandeira, Leonardo
Lewiecki, E. Michael
Bilezikian, John P.
Venue: Expert Opinion on Biological Therapy
Publisher: Informa UK Limited
Published: 2017-01-19
Volume: 17
Issue: 2
Pages: 255-263
ISSN: 1471-2598 (ISSN-L)
1744-7682
DOI: 10.1080/14712598.2017.1280455
OpenAlex: W2571025776
Cited by: 101
References: 75
Citations by year: 2026: 3 · 2025: 7 · 2024: 12 · 2023: 10 · 2022: 18 · 2021: 15 · 2020: 21 · 2019: 9 · 2018: 3 · 2017: 3
FWCI: 10.83
Type: journal article
Language: en
Open access: closed
Locations: Expert Opinion on Biological Therapy (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords: romosozumab, sclerostin, osteoporosis, postmenopausal osteoporosis, Wnt signaling, bone formation, bone mineral density, bone resorption, fracture risk, anabolic therapy, monoclonal antibodies, pharmacokinetics, pharmacodynamics, safety and tolerability
MeSH terms: Animals, Antibodies, Monoclonal, Clinical Trials as Topic, Female, Humans, Osteogenesis, Osteoporosis, Bone Density, Osteoporosis, Postmenopausal, Treatment Outcome, Bone Density Conservation Agents, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Romosozumab for the treatment of osteoporosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks